TY - JOUR
T1 - Somatic complaints in anxious youth
AU - Crawley, Sarah A.
AU - Caporino, Nicole E.
AU - Birmaher, Boris
AU - Ginsburg, Golda
AU - Piacentini, John
AU - Albano, Anne Marie
AU - Sherrill, Joel
AU - Sakolsky, Dara
AU - Compton, Scott N.
AU - Rynn, Moira
AU - McCracken, James
AU - Gosch, Elizabeth
AU - Keeton, Courtney
AU - March, John
AU - Walkup, John T.
AU - Kendall, Philip C.
N1 - Funding Information:
Acknowledgments This research was supported by grants (U01 MH064089, to Dr. Walkup; U01 MH64092, to Dr. Albano; U01 MH64003, to Dr. Birmaher; U01 MH63747, to Dr. Kendall, U01 MH64107, to Dr. March; U01 MH64088, to Dr. Piacentini; and U01 MH064003, to Dr. Compton) from the National Institute of Mental Health. Sertraline and matching placebo were supplied free of charge by Pfizer. Views expressed within this article represent those of the authors and are not intended to represent the position of NIMH, NIH, or DHHS.
PY - 2014/8
Y1 - 2014/8
N2 - This study examined (a) demographic and clinical characteristics associated with physical symptoms in anxiety-disordered youth and (b) the impact of cognitive-behavioral therapy (Coping Cat), medication (sertraline), their combination, and pill placebo on physical symptoms. Youth (N = 488, ages 7-17 years) with a principal diagnosis of generalized anxiety disorder, separation anxiety disorder, or social phobia participated as part of a multi-site, randomized controlled trial and received treatment delivered over 12 weeks. Diagnostic status, symptom severity, and impairment were assessed at baseline and week 12. The total number and severity of physical symptoms was associated with age, principal diagnosis, anxiety severity, impairment, and the presence of comorbid internalizing disorders. Common somatic complaints were headaches, stomachaches, head cold or sniffles, sleeplessness, and feeling drowsy or too sleepy. Physical symptoms decreased over the course of treatment, and were unrelated to treatment condition. Clinical implications and directions for future research are discussed (ClinicalTrials.gov number, NCT00052078).
AB - This study examined (a) demographic and clinical characteristics associated with physical symptoms in anxiety-disordered youth and (b) the impact of cognitive-behavioral therapy (Coping Cat), medication (sertraline), their combination, and pill placebo on physical symptoms. Youth (N = 488, ages 7-17 years) with a principal diagnosis of generalized anxiety disorder, separation anxiety disorder, or social phobia participated as part of a multi-site, randomized controlled trial and received treatment delivered over 12 weeks. Diagnostic status, symptom severity, and impairment were assessed at baseline and week 12. The total number and severity of physical symptoms was associated with age, principal diagnosis, anxiety severity, impairment, and the presence of comorbid internalizing disorders. Common somatic complaints were headaches, stomachaches, head cold or sniffles, sleeplessness, and feeling drowsy or too sleepy. Physical symptoms decreased over the course of treatment, and were unrelated to treatment condition. Clinical implications and directions for future research are discussed (ClinicalTrials.gov number, NCT00052078).
KW - Adolescents
KW - Anxiety
KW - Children
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84903484488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903484488&partnerID=8YFLogxK
U2 - 10.1007/s10578-013-0410-x
DO - 10.1007/s10578-013-0410-x
M3 - Article
C2 - 24129543
AN - SCOPUS:84903484488
SN - 0009-398X
VL - 45
SP - 398
EP - 407
JO - Child Psychiatry and Human Development
JF - Child Psychiatry and Human Development
IS - 4
ER -
